TIDMFIPP
Frontier IP Group plc
14 June 2019
RNS Reach
AIM: FIPP
14 June 2019
Frontier IP Group Plc
("Frontier IP" or the "Group")
Portfolio news - Exscientia expands international collaborations
with AI drug discovery partnership with GT Apeiron Therapeutics
Frontier IP, a specialist in commercialising university
intellectual property, is pleased to note the following
announcement from portfolio company Exscientia ("Exscientia" or the
"Company"), a world leader in artificial intelligence ("AI") drug
discovery, that it has entered into a drug-discovery partnership
with GT Apeiron Therapeutics ("GT Apeiron").
GT Apeiron is a Shanghai-headquartered biotechnology
drug-discovery platform launched with US$27 million backing from GT
Healthcare Capital Partners ("GT Healthcare"), a life
sciences-focused private equity partnership. GT Healthcare is also
an investor in Exscientia.
As part of the agreement, Exscientia is entitled to become a
shareholder in GT Apeiron as well as receiving milestones and
royalties based on the clinical and commercial success of each
programme.
GT Healthcare invested in Exscientia as part of a Series B
financing round, which raised US$26 million to scale up the
Company's pipeline and advance selected programmes towards clinical
development. Further details were announced by Frontier IP on 7
January 2019.
Exscientia's existing partnerships include collaborations with
Celgene, GSK, Roche, Sanofi and Evotec.
Frontier IP holds a 3.32 per cent stake in the Company.
Exscientia statement in full:
EXSCIENTIA EXPANDS INTERNATIONAL COLLABORATIONS WITH
SHANGHAI-HEADQUARTERED GT APEIRON THERAPEUTICS
FIRM ENTERS A MULTI-TARGET AI DRUG DISCOVERY PARTNERSHIP WITH
INITIAL FOCUS ON ONCOLOGY
Oxford, UK, June 2019: Exscientia, a world-leading Artificial
Intelligence (AI)-driven drug discovery company, announced today
that it has entered an AI drug discovery partnership with
Shanghai-headquartered GT Apeiron Therapeutics ("GT Apeiron").
The collaboration will use Exscientia's full-stack AI drug
discovery capabilities and GT Apeiron's proprietary technologies to
accelerate the development of novel drugs via new pathways to
tackle high impact therapeutic targets with an initial focus on
oncology.
As part of the agreement, Exscientia is entitled to become a
shareholder in GT Apeiron as well as receiving milestones and
royalties based on the clinical, regulatory and commercial success
of each programme. GT Apeiron was launched by GT Healthcare Capital
Partners, a life science-focused private equity partnership, with
$27 million financial backing.
Exscientia will use its cutting-edge Centaur Chemist(TM) AI drug
discovery platform, which has demonstrated its unparalleled
capability to deliver novel drug candidates with unprecedented
speed and efficiency. Taking advantage of China's investment in the
pharmaceutical space and using AI to improve the speed of discovery
of new treatments for patients both in China and globally are key
goals of this collaboration.
Exscientia's existing partnerships include collaborations with
Celgene, Roche, GSK, Sanofi and Evotec, cementing Exscientia's
international reputation as a leader in the rapidly developing
field of AI-driven drug discovery.
For Exscientia, this partnership is an opportunity to continue
its global expansion and replicate its success in China. The
partnership comes just a few months after Exscientia announced the
opening of its Osaka office, strengthening its footprint in
Asia.
Professor Andrew Hopkins, Exscientia's CEO, commented: "This is
an exciting time for pharmaceutical research, with innovative
approaches to drug discovery as well as the development of new
commercial markets. Both are strongly evident in China, already the
second largest national pharmaceutical market in the world, where
we are delighted to join our expertise and technology with GT
Apeiron to initiate our first discovery opportunity in the country.
The medicines we generate by applying our AI platform and GT
Apeiron's experimental expertise will focus on areas of significant
unmet need with global potential."
Dr. Mingxi Li, board member of GT Apeiron said: "We are
delighted to partner with the world leading AI-driven drug
discovery company who will also become a shareholder of GT Apeiron.
We believe the joint effort will significantly improve drug R&D
productivity to benefit patients."
Exscientia statement ends
ENQUIRIES
Frontier IP Group Plc T: 020 7332 2338
Neil Crabb, Chief Executive
Andrew Johnson, Communications & Investor M: 07464 546 025
Relations
Company website: www.frontierip.co.uk
Allenby Capital Limited (Nominated Adviser T: 0203 328 5656
and Broker)
Nick Athanas / Nicholas Chambers (Corporate
Finance)
Amrit Nahal (Equity Sales)
Exscientia Limited
Corporate enquiries:
Mark Swindells, Chief Operating Officer
Company website: www.exscientia.co.uk contact@exscientia.co.uk
Twitter: www.twitter.com/exscientialtd
Exscientia media enquiries:
Edelman
exscientia@edelman.com
Sesh Rahim +44(0) 203 047 4207
Camille Oster +44(0) 7812660934
NOTES FOR EDITORS
About Exscientia
Exscientia is at the forefront of Artificial Intelligence
(AI)-driven drug discovery and design. By fusing the power of AI
with the discovery experience of seasoned drug hunters, Exscientia
is the first company to automate drug design, surpassing
conventional approaches.
Exscientia's innovative Centaur Chemist(TM) platform enables
breakthrough productivity gains as well as new approaches to
improve drug efficacy. Novel compounds are automatically designed
and prioritised for synthesis by its AI systems, which rapidly
evolve compounds towards the desired candidate criteria for
clinical development.
Exscientia systems learn from both existing data resources and
experimental data from each design cycle. The principle is similar
to how a human would learn, but the AI process is far more
effective at identifying and assimilating multiple subtle and
complex trends to balance potency, selectivity and pharmacokinetic
criteria. As a result, the AI-driven process is more likely to
achieve the end goal and to do this more rapidly and efficiently
than traditional human endeavour.
Exscientia is collaborating with several leading pharmaceutical
and life sciences companies, including Celgene, GSK, Sanofi, Roche
and Evotec.
Exscientia has its headquarters in Oxford, UK with offices in
the UK, USA and Japan. For more information visit us on
www.exscientia.co.uk or follow us on Twitter @exscientialtd
ABOUT GT APEIRON THERAPEUTICS
GT Apeiron Therapeutics was launched in 2019 by GT Healthcare
Capital Partners. It is a Shanghai-headquartered biotechnology
platform utilizing state-of-the-art technologies for drug
discovery.
ABOUT GT HEALTHCARE CAPITAL PARTNERS
GT Healthcare Capital Partners is an Asia-based private equity
firm that specializes in life science investments around the globe
that aim to benefit patients. GT Healthcare aims to provide capital
and scale expertise to healthcare businesses in Asia / Greater
China.
ABOUT FRONTIER IP
Frontier IP unites science and commerce by identifying strong
intellectual property and accelerating its development through a
range of commercialisation services. A critical part of the Group's
work is involving relevant industry partners at an early stage of
development to ensure technology meets real world demands and
needs.
The Group looks to build and grow a portfolio of equity stakes
and licence income by taking an active involvement in spin-out
companies, including support for fund raising and collaboration
with relevant industry partners at an early stage of
development.
ABOUT RNS REACH ANNOUNCEMENTS
This is an RNS Reach announcement. RNS Reach is an investor
communication service aimed at assisting listed and unlisted
(including AIM quoted) companies to distribute media only /
non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABLGDLBGBBGCX
(END) Dow Jones Newswires
June 14, 2019 02:00 ET (06:00 GMT)
Frontier Ip (LSE:FIPP)
Historical Stock Chart
From Apr 2024 to May 2024
Frontier Ip (LSE:FIPP)
Historical Stock Chart
From May 2023 to May 2024